Skip to main content
SpringerLink
Log in

Molecular Monitoring of Chronic Myeloid Leukemia

  • Protocol
  • First Online:
Book cover Quantitative Real-Time PCR

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2065))

Abstract

Molecular diagnosis and measurement of minimal residual disease (MRD) in patients with chronic myeloid leukemia (CML) is essential for clinical management. In the era of tyrosine kinase inhibitor therapy molecular tests including BCR-ABL1 transcript monitoring and kinase domain mutation analysis are the main tools used to inform choice of treatment, appropriate dosage and even whether therapy can be safely withdrawn. Quantitation of BCR-ABL1 oncogene transcript by real-time quantitative PCR (qPCR) is currently the gold-standard method for monitoring as it provides superior sensitivity over karyotyping and fluorescent in situ hybridization (FISH). Here we describe step-by-step methods of RNA conversion to cDNA along with the qPCR protocol which is used in one of the main reference laboratories for this test.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Nowell PC, Hungerford DA (1960) Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 25:85–109

    CAS  PubMed  Google Scholar 

  2. Rowley JD (1973) Chromosomal patterns in myelocytic leukemia. N Engl J Med 289:220–221. https://doi.org/10.1056/NEJM197307262890421

    Article  CAS  PubMed  Google Scholar 

  3. Khorashad JS, Deininger MW (2011) Selection of therapy: rational decisions based on molecular events. Hematol Oncol Clin North Am 25:1009–1023., vi. https://doi.org/10.1016/j.hoc.2011.09.006

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kantarjian HM, Keating MJ, Talpaz M et al (1987) Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 83:445–454

    Article  CAS  PubMed  Google Scholar 

  5. Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118:3123–3127. https://doi.org/10.1002/cncr.26679

    Article  PubMed  Google Scholar 

  6. Druker BJ, Guilhot F, O’Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408–2417. https://doi.org/10.1056/NEJMoa062867

    Article  CAS  PubMed  Google Scholar 

  7. Eissa H, Gooley TA, Sorror ML et al (2011) Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant 17:908–915. https://doi.org/10.1016/j.bbmt.2010.09.018

    Article  PubMed  Google Scholar 

  8. Melo JV, Gordon DE, Cross NC et al (1993) The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 81:158–165

    CAS  PubMed  Google Scholar 

  9. Cross NC, Melo JV, Feng L et al (1994) An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 8:186–189

    CAS  PubMed  Google Scholar 

  10. Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884. https://doi.org/10.1182/blood-2013-05-501569

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cross NC, White HE, Colomer D et al (2015) Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 29:999–1003. https://doi.org/10.1038/leu.2015.29

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cross NC, Hochhaus A, Muller MC (2015) Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Ann Hematol 94(Suppl 2):S219–S225. https://doi.org/10.1007/s00277-015-2315-1

    Article  CAS  PubMed  Google Scholar 

  13. Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343–3356

    CAS  PubMed  Google Scholar 

  14. Roman J, Jimenez A, Barrios M et al (2001) E1A3 as a unique, naturally occurring BCR-ABL transcript in an indolent case of chronic myeloid leukaemia. Br J Haematol 114:635–637

    Article  CAS  PubMed  Google Scholar 

  15. Jinawath N, Norris-Kirby A, Smith BD et al (2009) A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice. J Mol Diagn 11:359–363. https://doi.org/10.2353/jmoldx.2009.090008

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Laurent E, Talpaz M, Kantarjian H et al (2001) The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res 61:2343–2355

    CAS  PubMed  Google Scholar 

  17. Claudiani S, Apperley JF, Gale RP et al (2017) E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica 102:e297–e299. https://doi.org/10.3324/haematol.2017.168740

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hanfstein B, Lauseker M, Hehlmann R et al (2014) Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica 99:1441–1447. https://doi.org/10.3324/haematol.2013.096537

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Melo JV (1996) The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88:2375–2384

    CAS  PubMed  Google Scholar 

  20. Li S, Ilaria RL Jr, Million RP et al (1999) The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 189:1399–1412

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Wittwer CT, Herrmann MG, Moss AA et al (1997) Continuous fluorescence monitoring of rapid cycle DNA amplification. BioTechniques 22:130–131. 134–138

    Article  CAS  PubMed  Google Scholar 

  22. Holland PM, Abramson RD, Watson R et al (1991) Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A 88:7276–7280

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Livak KJ, Flood SJ, Marmaro J et al (1995) Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl 4:357–362

    Article  CAS  PubMed  Google Scholar 

  24. White H, Deprez L, Corbisier P et al (2015) A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. Leukemia 29:369–376. https://doi.org/10.1038/leu.2014.217

    Article  CAS  PubMed  Google Scholar 

  25. Wang YL, Lee JW, Cesarman E et al (2006) Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts. J Mol Diagn 8:231–239. https://doi.org/10.2353/jmoldx.2006.040404

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gerrard G, Mudge K, Foskett P et al (2012) Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: innovation, automation, and harmonization. Am J Hematol 87:717–720. https://doi.org/10.1002/ajh.23212

    Article  PubMed  Google Scholar 

  27. Collins SJ (1987) The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 70:1233–1244

    CAS  PubMed  Google Scholar 

  28. Bustin SA, Benes V, Garson JA et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55:611–622. https://doi.org/10.1373/clinchem.2008.112797

    Article  CAS  PubMed  Google Scholar 

  29. Kutyavin IV, Afonina IA, Mills A et al (2000) 3′-minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res 28:655–661

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Westgard JO, Barry PL, Hunt MR et al (1981) A multi-rule Shewhart chart for quality control in clinical chemistry. Clin Chem 27:493–501

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Imperial Molecular Pathology, Hammersmith Hospital, Imperial College Healthcare, London, UK

    Katherine Dominy, Katya Mokretar, Alistair G. Reid & Jamshid S. Khorashad

  2. Centre for Haematology, Hammersmith Hospital, Imperial College London, London, UK

    Jamshid S. Khorashad

Authors
  1. Katherine Dominy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katya Mokretar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alistair G. Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jamshid S. Khorashad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jamshid S. Khorashad .

Editor information

Editors and Affiliations

  1. Molecular Diagnostics, IRCCS, Istituto Giannina Gaslini, Genova, Italy

    Roberto Biassoni

  2. ASL3 Sistema Sanitario Regione Liguria, S.C. Laboratorio d’Analisi, Genova, Italy

    Alessandro Raso

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Dominy, K., Mokretar, K., Reid, A.G., Khorashad, J.S. (2020). Molecular Monitoring of Chronic Myeloid Leukemia. In: Biassoni, R., Raso, A. (eds) Quantitative Real-Time PCR. Methods in Molecular Biology, vol 2065. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9833-3_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-9833-3_12

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-4939-9832-6

  • Online ISBN: 978-1-4939-9833-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation